Novel Chinese Medicine Formula for Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 162 participants.

Also called NCT06978023

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 162 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06978023
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Hong Kong SAR China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06978023. Randomized; quadruple masking; primary purpose treatment. Start 2025-05 (anticipated); primary completion 2026-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Novel Chinese Medicine Formula for Diabetes
Intervention (Combination product)
JM-LD
Intervention (Combination product)
JM-HD
Intervention (Combination product)
Placebo
Lead sponsor
Chinese University of Hong Kong (class: other)

Record details

Record id
cardio:ct-nct06978023
Content hash
ccf7b0581880ea34b9e868b9b4fba4442b5748ad29b01d041c4df6366cc3c4a4